Jul 22, 2026 04:30PM
Jul 22, 2026 04:30PM
Apr 20, 2026 06:45AM
Apr 20, 2026 06:45AM
Oct 21, 2025 07:30PM
Oct 21, 2025 07:30PM
May 30, 2024 10:30PM U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
Jan 8, 2024 06:30PM
Nov 30, 2023 05:00PM
Nov 30, 2023 05:00PM
Aug 23, 2023 06:45AM
Aug 10, 2023 08:35AM
Jul 6, 2023 02:00AM
Apr 30, 2023 09:24PM Astellas Pharma to acquire Iveric Bio (ISEE) for $5.9 billion
Apr 30, 2023 07:00PM
Apr 30, 2023 07:00PM
Feb 19, 2023 06:30PM
Dec 20, 2022 06:45AM
Dec 20, 2022 06:45AM
Aug 18, 2022 02:30AM
Jan 6, 2021 08:00AM FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq® (mirabegron) Tablets in Pediatric Patients
Oct 14, 2020 07:08AM
Oct 14, 2020 07:00AM
Dec 2, 2019 08:04AM
Dec 2, 2019 08:00AM
Dec 2, 2019 08:00AM
Sep 16, 2019 08:00AM
Sep 16, 2019 08:00AM Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Aug 21, 2019 02:00PM
Aug 21, 2019 02:00PM
May 29, 2018 08:00AM
Mar 19, 2018 04:16PM
Mar 19, 2018 04:15PM
Mar 19, 2018 04:15PM
Sep 12, 2017 10:00PM U.S. FDA Accepts for Review Astellas' Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
Feb 22, 2016 04:10PM
Feb 22, 2016 04:10PM

15,610 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All